Validation of the Glasgow Antipsychotic Side-Effect Scale (GASS) in an Italian Sample of Patients with Stable Schizophrenia and Bipolar Spectrum Disorders
Authors:
- Alessandro RodolicoARAlessandro Rodolico
- Carmen ConcertoCarmen Concerto
- Alessia CiancioACAlessia Ciancio
- Spyridon SiafisSSSpyridon Siafis
- Laura Fusar-PoliLFLaura Fusar-Poli
- Carla Benedicta RomanoCRCarla Benedicta Romano
- Elisa Vita ScavoESElisa Vita Scavo
- Antonino PetraliaAPAntonino Petralia
- Salvatore SalomoneSSSalvatore Salomone
- Maria Salvina SignorelliMaria Salvina Signorelli
- Stefan LeuchtSLStefan Leucht
- Eugenio AgugliaEugenio Aguglia
Open Access
- 7 July 2022
- journal article
- research article
- Published by MDPI AG in Brain Sciences
- Vol. 12 (7) , 891
Abstract
Antipsychotics are a class of psychotropic drugs that improve psychotic symptoms and reduce relapse risk. However, they may cause side effects (SE) that impact patients’ quality of life and psychosocial functioning. Therefore, there is a need for practical tools to identify them and possibly intervene. The objective of the present study was to translate into Italian the Glasgow Antipsychotic Side Effect Scale (GASS), which is suggested as the questionnaire of choice to collect SE reported by patients treated with antipsychotics. We administered the GASS and the Udvalg for Kliniske Undersøgelser (UKU) SE scale—which is considered the gold standard—to 100 stable patients with schizophrenia and bipolar spectrum disorders. We measured the structural validity, internal consistency, concurrent criterion validity, construct validity, and clinical feasibility. GASS was characterized by modest structural validity and good internal consistency. The binary correlations concerning the presence of specific symptoms investigated with the GASS and the UKU were strong or relatively strong for only half of them. The GASS total scale score was inversely related to patients’ quality of life and psychosocial functioning. The GASS is useful to briefly assess the burden of antipsychotic SE (~5 min) but is not optimal in identifying them.Keywords
Funding Information
- POC Sicilia 2014-20—Avviso 37/2020 (G67C20000210002)
This publication has 36 references indexed in Scilit:
- A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophreniaBMC Psychiatry, 2012
- Translation, adaptation and validation of instruments or scales for use in cross‐cultural health care research: a clear and user‐friendly guidelineJournal of Evaluation in Clinical Practice, 2010
- Developing the World Health Organization Disability Assessment Schedule 2.0Bulletin of the World Health Organization, 2010
- A new self-rating scale for detecting atypical or second-generation antipsychotic side effectsJournal of Psychopharmacology, 2008
- Validity of the EQ-5D in assessing and valuing health status in patients with schizophrenic, schizotypal or delusional disordersEuropean Psychiatry, 2007
- Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia: Clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat)Nordic Journal of Psychiatry, 2001
- Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternativesStructural Equation Modeling: A Multidisciplinary Journal, 1999
- A Self-Rating Scale for Measuring Neuroleptic Side-EffectsThe British Journal of Psychiatry, 1995
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990
- The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patientsActa Psychiatrica Scandinavica, 1987